Warning: This post contains mentions of bullying, eating disorders, suicide, alcoholism, and drugs.
J. Shearer / WireImage via Getty Images
Steve Grayson / WireImage via Getty Images
Related: "Kylie Jenner's Latest Vlog Has Everyone Debating Her Extravagant Life"
HBO Max / The Howard Stern Show / Via youtube.com

#wireimage #images #steve #kylie

Internet personality and streamer Meep (meepiosaurus) revealed that she was married at 19. It wasn't a fairy tale, and she told TikTok about the red flags leading up to her wedding.
"At this moment, I was separating myself from my family," Meep prefaced her story. Now divorced, she claimed her husband "wasn't the best" in terms of character. Furthermore, she alleged that he had been physically abusive but didn't go into detail about it.
"The beginning of that pattern starts with them taking you away from your family and your friends, kind of ostracizing you from your support system," she alleged. A former prosecutor has also described dangerous men and the characteristics they have in common. Meep now recognizes the pattern, but couldn't when she was 19.
"So, I remember my dad and I were besties at the time, and I started really detaching myself from him. Stopped going to therapy," Meep said. At the time, she was supposed to be tested for bipolar disorder, but didn't push through. She told her dad she was getting married the next day while they were in a parking lot.
"I remember it was one of those conversations that was heavy, okay? And I could tell there was something more happening in that conversation, and it was something I wasn't picking up on," Meep recalled. She said she knew she was making a mistake, and her father also advised her. He allegedly told her not to sign any contract that indicated she was married to her then-boyfriend. Meep believes her dad saw through her boyfriend and thought he was taking advantage of her.

#myself

For spring 2027, Vincent Garnier Pressiat transformed a floor of the recently reopened Bus Palladium — where stars like Serge Gainsbourg and Mick Jagger stayed in the 1970s — into an intimate stage for a woman in the messy aftermath of a breakup.
Guests were invited behind room doors to discover scenes of morning-after disorder: one model struggled to light a cigarette in front of a fan, another got a tattoo on a bed and a third stood beside the sofa holding a chainsaw. On a room-service trolley, a vibrator sat on a dirty plate.
More from WWD
Carla Bruni, Karen Elson Celebrate Mert Alas' Donna Karan Campaign Return in Paris
Bonpoint Is Launching Sport and Couture Categories

#vincent #pressiat #serge #guests

Paloma Elsesser thinks that the glamorization of Ozempic and similar weight-loss drugs isn't a good thing for society as a whole.
The 34-year-old model, who became the first plus-size model to win Model of the Year at the Fashion Awards in 2023, made an appearance on Vogue's The Run-Through podcast and suggested the rise of Ozempic can be correlated to the rise of "conservative" and "anti-woke" rhetoric. "I think the Ozempic era that we're talking about is harmful because it kind of takes away the agency to live in the way that I would hope people and women and young girls and young people can think about their bodies in this world," she shared. Around the 32-minute point of the podcast, which can be seen above.
Elssesser also said that she's seen a rise in "pro-eating disorder content" on platforms such as TikTok, which is especially worrying considering so many young people have unfiltered access to such content.
"II think people are just being like, 'Okay, this is not it,'" she continued. "We're seeing celebrities and people… I think people are upset. … I think that women should have agency. I am critical of applying my body, your body, your choice to this conversation because it's like… 'Is it your choice?' It's not. It's a prescription, so it doesn't actually feel like a choice. … I don't know, maybe I said something problematic. … The number one central tenet, like, anything that I try and live and encourage is to just think critically, not be critical."
COMPLEX SHOP: Shop the brands you love, anytime and anywhere. Uncover what's next. Buy. Collect. Obsess.

#ozempic #choice

The failed execution of Christa Pike in Tennessee on Wednesday has added new fuel to the longstanding debate over the death penalty in the United States. It has also drawn new scrutiny to the question of whether lethal injection, the nation's primary method of execution for the past 40 years, is truly a "more humane" alternative to other ways of putting someone to death.
Pike was given a death sentence in 1996 after being convicted of killing her classmate, Colleen Slemmer, in an attack she carried out with her then boyfriend. After 30 years on death row, and a last-minute legal battle that temporarily delayed her execution, Pike was scheduled to be put to death on Wednesday night.
However, the two doses of pentobarbital she was given proved not to be fatal. According to witnesses, Pike remained alive and snored loudly for 40 minutes after the drugs were administered. Eventually, the execution was called off and she was taken to the hospital for treatment.
Pike's attorney Randy Spivey reported Thursday afternoon that she was in critical condition and receiving "life-saving care." She was unconscious and placed on a ventilator in the hospital, according to a filing by her legal team on Friday.
Spivey admonished the state for going forward with lethal injection despite his warnings ahead of time that a blood-clotting disorder called thrombocytosis "would cause her to suffer an agonizing death." Pike's attorneys had asked the courts to permit her to die by hanging, but the request was denied.

#pike #years #given

Alex Dougherty has said, "Social media saved me."
He's the oldest of 11 kids and part of one of the most popular families on the internet, known as the Dougherty Dozen by their 7.8 million TikTok followers.
Like many people, his mom, Alicia, joined TikTok during the COVID-19 pandemic. She began posting about their extra-large family in 2020, when Alex was 14.
The appeal is simple: Viewers want to see what raising so many children is like, from the everyday to the extraordinary challenges. Seven of the Dougherty kids are adopted, and six have been diagnosed with fetal alcohol spectrum disorders (FASD). Over time, viewers have gotten to know each kid as they grow up.

#like

Bruce Willis has reportedly settled into a routine amid his struggle with frontotemporal dementia (FTD), a degenerative brain disease that damages the frontal and temporal lobes.
The actor retired in spring 2022 following an initial aphasia diagnosis, a disorder that affects how you communicate, which was later revealed to be FTD after they received a more specific diagnosis in 2023.
Now, sources close to Bruce Willis claim that he knows he is deeply loved and cared for, but his ability to communicate remains limited three years after his diagnosis was first shared publicly.
MEGA
According to sources close to the family, Willis has maintained a daily routine that focuses on keeping him active and in regular contact with his relatives.

#willis #according

Definium Therapeutics, Inc. (NASDAQ:DFTX) has now delivered a third consecutive positive Phase 3 readout for its LSD-based medication, the second in generalized anxiety disorder. The result puts the company on a viable route toward a potential FDA approval of an LSD-based treatment for generalized anxiety disorder, and considering how closely psychedelic stocks have historically traded on each other's data, the reading carries far more weight than Definium's own ticker.
On September 14, Definium Therapeutics, Inc. (NASDAQ:DFTX) announced that its drug DT120, an orally disintegrating tablet formulation of LSD, was successful in Panorama, the company's second late-stage anxiety trial. Over 12 weeks, patients who received a 100-microgram dose experienced a 9.8-point decline on the Hamilton Anxiety Rating Scale, a typical clinical measure, compared to a 4.7-point drop with placebo.
The resulting 5.1-point placebo-adjusted improvement is similar to what the company's first pivotal anxiety trial, Voyage, showed back in August: an 11.6-point improvement versus 6.2 for placebo, a 5.4-point separation that Jefferies called one of the strongest placebo-adjusted efficacy results ever seen in generalized anxiety disorder, and that Stifel simply described as "a clean win."
Psychedelic equities have a history of trading as a group rather than as individual names, and this tendency applies both ways. In February 2026, when Compass Pathways, the sector's other clinical leader developing a psilocybin-based drug for treatment-resistant depression, reported positive late-stage data, shares of Definium Therapeutics, Inc. (NASDAQ:DFTX), Atai Beckley, GH Research, and Helus Pharma all rose, some by double digits.
That correlation is significant here because Definium's win is an independent validation of the broader therapeutic argument on which Compass and others are betting: a single dose of a classic psychedelic, administered in a controlled clinical setting, can produce lasting improvements in serious mental health conditions via pathways different from existing SSRIs and other standard-of-care drugs.

#definium #placebo

Xenon Pharmaceuticals (XENE) shares crashed on Friday after the biopharmaceutical firm said it has paused new patient enrollment in its clinical trials evaluating azetukalner. As investors responded to the setback involving XENE's lead drug candidate for major depressive disorder, its relative strength index (RSI) slipped into the early teens, indicating extremely oversold conditions.
Following today's decline, Xenon Pharmaceuticals stock is trading nearly 40% below its year-to-date high.
Bank of America Just Declared a 'Generational Entry Point' in U.S. Bonds. Why Investors Should Be Backing Up the Truck on Treasuries Here.
Mark Cuban Says He Was Dizzy for Months, So He Built a VR Fix That Does at Home 'Much Of What A 180k Machine' Does
JPMorgan Gives Up Forecasting Iran War Endgame as Trump Tells Reporters 'Anything Could Happen With Me'

#xene #following #America

With a market cap of $18.8 billion, Zimmer Biomet Holdings, Inc. (ZBH) is a global medical technology company specializing in musculoskeletal healthcare solutions. The company designs, manufactures, and markets products ranging from orthopedic reconstructive implants to sports medicine, spine, craniomaxillofacial, and thoracic solutions.
Companies worth more than $10 billion are generally labeled as "large-cap" stocks and Zimmer Biomet fits this criterion perfectly. Its innovations support surgeons and healthcare providers worldwide in treating disorders and injuries of bones, joints, and soft tissues.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
Why It's Time to Load Up on Nvidia Stock
The Case for Selling CrowdStrike Stock

#Stock

Fourteen years ago, Ken Jouppi, who had operated a charter airplane business in Alaska since the 1970s, agreed to fly a passenger from Fairbanks to Beaver, one of the state's dry jurisdictions. The passenger's luggage included 72 cans of Budweiser and Bud Light, which she planned to share with her husband on his birthday. Although most of the beer was boxed, a six-pack "was packed only in a grocery bag and would have been in plain view to Jouppi as he was loading the airplane," the Alaska Supreme Court noted last year.
State troopers discovered the beer before the plane took off, and Jouppi was convicted of a misdemeanor. The trial court, which concluded that Jouppi had been "willfully blind" to the six-pack, sentenced him to three days in jail and a $1,500 fine. But state law mandated another punishment that was 63 times as severe: forfeiture of Jouppi's $95,000 airplane. Although that penalty seemed grossly disproportionate, the Alaska Supreme Court ruled that it did not violate the Eighth Amendment's ban on excessive fines.
In July, responding to a petition filed by the Institute for Justice, the U.S. Supreme Court agreed to review that decision. It will hear oral argument in Jouppi v. Alaska on December 1. In a brief supporting Jouppi's appeal that it filed last week, the Cato Institute argues that the Alaska Supreme Court erred by failing to consider the gravity of his conduct and the financial consequences of the forfeiture. Both of those factors, Cato attorney Matthew Cavedon says, have been central to the common-law understanding of excessive fines for eight centuries.
"The Eighth Amendment was designed to prevent this kind of abuse by limiting excessive fines," Cavedon writes. "Long before the United States was founded, the common law protected people from extreme monetary penalties. But the Alaska Supreme Court's view is that challenges to excessive fines 'should rarely succeed.' This dismissive view led it to conclude that there is nothing excessive about the forfeiture of an airplane worth 'only 9.5 times the maximum fine'—and over 60 times the fine actually imposed. The decision below cannot be reconciled with this Court's precedent or the Excessive Fines Clause's original meaning."
In weighing the proportionality of the airplane forfeiture, the Alaska Supreme Court thought the relevant consideration was the harm caused by excessive drinking. "Alcohol abuse in rural Alaska leads to increased crime; disorders, such as alcoholism; conditions, such as fetal alcohol spectrum disorder; and death, imposing substantial costs on public health and the administration of justice," Justice Jude Pate wrote in the majority opinion. "Within this context, it is clear that the illegal importation of even a six-pack of beer causes grave societal harm."

#court #excessive #jouppi

Iowa wrestler Jordan Williams has been charged with operating while under the influence, according to Johnson County court records.
This is Williams' second OWI charge, according to court documents, with the first coming in Payne County, Oklahoma, in August 2023.
The incident occurred Sept. 7. According to a police affidavit, an officer approached a vehicle that had been running with its lights on for "at least" two hours in a parking lot/garage at 180 E. Burlington St. in Iowa City. The officer found Williams unconscious with an open container of alcohol in his lap.
The police affidavit states that after Williams woke up, the officer observed an alcohol smell, slurred speech and bloodshot eyes, as well as Williams showing impairment in standardized field sobriety tests. Williams refused a preliminary breath test, according to the police affidavit.
This is Williams' second off-the-mat incident since committing to Iowa in 2025. On June 14, 2025, while Williams was publicly committed to Iowa but not yet signed, he was involved in an incident at ReUnion Brewery in Iowa City. He and his attorney later agreed to an amended plea of a simple misdemeanor charge for disorderly conduct.

#affidavit

(NewsNation) — A new study found that a rare but serious brain condition has been identified in a small number of people taking popular weight-loss drugs such as Ozempic, Wegovy, Mounjaro and Zepbound.
Wernicke encephalopathy is a rare neurological disorder caused by a severe deficiency of vitamin B1, also known as thiamine.
GLP-1 prescriptions for kids up more than 30,000% since 2019
Researchers identified 15 cases reported in 2023 and 2024 among people taking GLP-1 medications containing semaglutide, found in Ozempic and Wegovy, or tirzepatide, found in Mounjaro and Zepbound.
Vitamin B1 is essential for proper nerve function. Without enough of it, patients can develop confusion, problems with balance and coordination, and abnormal eye movements.

#zepbound #vitamin #identified

R&B singer Bilal is facing allegations from Jamila Raegan, the mother of his adult son Bashir, who claims the artist has left her to handle their son's care alone. In an emotional Instagram post, Raegan also accused Bilal, whose full name is Bilal Oliver, of abuse and said she had protected him for more than half her life. "I'm not okay because I've spent over half of my life protecting an abuser," she wrote before identifying the singer by name.
Raegan said Bashir has multiple disabilities, including autism and bipolar disorder, and claimed Bilal has shown "complete disregard" while she manages their son's needs. "I am caring for him alone while his father continues to live his life," she wrote.
Raegan did not detail what **** istance she believes Bilal has withheld or provide specific information about her abuse allegation in the post.
COMPLEX SHOP: Shop the brands you love, anytime and anywhere. Uncover what's next. Buy. Collect. Obsess.
Bashir is a frequent presence on Raegan's Instagram page, where she has shared photos, videos, and personal updates about their life together over the years. In her latest message, she credited relatives, friends, and members of her community with helping support her.

#bilal #Instagram #shop

Martin O'Neill's side face Rangers in Sunday's Premier Sports Cup quarter-final, but there will be no travelling Celtic contingent at Ibrox.
It was confirmed last week that all SPFL meetings between the Glasgow rivals this season will be played without away supporters following disorder last term and the clubs' failure to reach an agreement over an allocation for this weekend's cup tie.
Former Celtic captain Brown believes the absence of away fans is stripping some of the passion and emotion from a fixture he relished during his playing career.
He said: "I understand why, but it's disappointing not to see the 8,000 fans that we used to get because the atmosphere was brilliant and there wasn't that much trouble back when I played.
"Going away from home you always want fans there because if you do score, you need somewhere to run. Celtic are going to score and they're going to run in front of Rangers fans.

#celtic #going #score

The pharmaceutical sector was hit with major pipeline news on September 1 when Novartis AG (NYSE:NVS) paused eight clinical trials of rap-cel, its experimental CAR-T cell therapy targeting autoimmune and neurological disorders. The suspension, effective August 24, followed three patient deaths caused by severe, life-threatening immune reactions (immune effector cell-associated hemophagocytic syndrome). Novartis is currently conducting a safety review alongside independent monitoring boards. Following the news, Bristol-Myers Squibb Company (NYSE:BMY) voluntarily paused trials for its competing CAR-T treatment, zola-cel, as a precautionary measure after detecting transient inflammatory side effects.
Looking at Q2 2026 earnings, Bristol Myers Squibb is currently demonstrating stronger financial momentum. Bristol-Myers Squibb Company (NYSE:BMY) reported total revenue of $13.0 billion, up 6% year over year, driven by a 15% increase in its Growth Portfolio to $7.6 billion, led by Opdivo, Qvantig, Reblozyl, and Camzyos. Non-GAAP EPS reached $2.04, while net income totaled $3.3 billion, or $4.2 billion on a non-GAAP basis. The company also raised its full-year 2026 revenue guidance from approximately $46.0–$47.5 billion to $49.0–$50.0 billion and increased its non-GAAP EPS outlook to $6.75–$7.00.
Novartis AG (NYSE:NVS), meanwhile, reported Q2 net sales of $14.4 billion, up 3% in U.S. dollars and 1% at constant currencies, supported by Kisqali and Kesimpta, which grew 43% and 32% at constant currencies, respectively. However, generic competition reduced growth by 14 percentage points, while core operating income remained flat at $5.9 billion and GAAP net income fell 19% to $3.3 billion. Novartis reaffirmed rather than raised its full-year guidance, calling for low single-digit sales growth and a low single-digit decline in core operating income.
Overall, Bristol Myers stands out as the stronger financial story this quarter, with its Growth Portfolio offsetting legacy patent-cliff pressures and supporting a guidance increase, while Novartis continues to contend with generic erosion weighing on earnings.
Novartis' bull case rests on strong double-digit growth from high-margin blockbusters such as Kisqali, Kesimpta, and Scemblix, supporting robust Q2 free cash flow of $5.6 billion. However, CAR-T safety setbacks could threaten a key pipeline platform, while intense generic competition has already reduced top-line growth by 14 percentage points.

#billion #novartis

Is it better to own a company already selling drugs or one with a potential blockbuster in testing? Investors are weighing Axsome Therapeutics (NASDAQ:AXSM) against Viking Therapeutics (NASDAQ:VKTX) to decide.
Axsome focuses on commercializing treatments for depression and sleep disorders, showing significant revenue growth. Viking is a clinical-stage developer targeting the massive obesity market but has no products on the market yet. Both represent different stages of growth within the biotech world, making them popular choices for healthcare-minded portfolios.
Axsome develops and sells treatments for central nervous system conditions such as depression, migraines, and narcolepsy. It is a prominent name among biotech stocks, with a portfolio that includes Auvelity, Sunosi, and Symbravo. The company recently entered a settlement that grants license rights to five generic manufacturers for Sunosi starting in 2040, providing long-term clarity on its patent life and market position. In its latest annual report, filed in early 2026, the company noted it had over 900 full-time employees to support its commercial reach.
In FY 2025, revenue reached nearly $638.5 million, marking growth of close to 65.5% compared to the prior year. This increase was driven by the continued expansion of its key central nervous system treatments into new geographic markets. The company reported a net loss of approximately $183.2 million, resulting in a negative net margin, which is the percentage of revenue left after all expenses are paid, of roughly 28.7%. Some investors focus on the P/S ratio to value the business relative to this growing revenue.
As of December 2025, the debt-to-equity ratio was nearly 2.7x, meaning the company uses significant debt relative to its equity. The current ratio of approximately 1.6x indicates it has $1.60 in ****** ets for every $1.00 in liabilities due within a year. Free cash flow, or cash from operations minus capital spending, was nearly negative $93.9 million as the company continues to invest in its commercial pipeline. This spending is intended to support the long-term growth of its approved products and the development of new candidates.

#ratio #therapeutics

Cindy Crawford commented on the comparisons she gets to daughter Kaia Gerber in a new interview with Porter magazine
The supermodel admitted that it might "suck" for her 25-year-old to have to "handle" being told she looks like her mom
Kaia revealed in her September 2026 Vogue cover interview that she struggled with "disordered eating" while growing up in the spotlight and having her image compared to that of her mom's
Cindy Crawford and Kaia Gerber are a reflection of each other, but how they feel about their similarities is different.
For years, the supermodel, 60, and her daughter, now 25, have been compared to each other in terms of their bombshell looks, careers and styles, and in a new interview with Porter magazine Crawford said that she loves it, but it might be more difficult for Kaia.

#kaia

Scotland midfielder Scott McTominay has had successful surgery on a minor heart issue and will return to training in two weeks' time, his club Napoli said on Tuesday.
The former Manchester United player recently experienced a heart rhythm disorder, something which is not considered serious but did require surgery.
"On Tuesday morning, Scott McTominay underwent an ablation procedure at Spire Manchester Hospital. The operation was a complete success," the Serie A club said in a statement.
"McTominay will rest for two weeks and then resume training."
McTominay, 29, has been a key player for Napoli since joining from Manchester United in 2024, scoring 27 goals in 82 matches.

#tuesday #heart #weeks

On August 12, Royalty Pharma (NASDAQ:RPRX) agreed to pay Zealand Pharma $100 million for the rights to future royalties on rusfertide, an experimental treatment for a rare blood disorder called polycythemia vera. It is Royalty Pharma's second collaboration with Zealand, and it arrives just as rusfertide awaits a decision from the FDA. For a company that makes its living buying pieces of other companies' drugs, the timing says a lot about how it weighs risk against reward before a regulatory verdict even lands.
Royalty Pharma's business depends on picking the right moment to buy into a drug's future, and this deal fits that pattern. Under the agreement, $50 million changes hands at closing and the remaining $50 million arrives on the first anniversary, in exchange for a 1% royalty on rusfertide's global sales plus any regulatory and commercial milestones. Rusfertide, a once-weekly self-injected therapy that mimics the hormone hepcidin to control iron levels in polycythemia vera patients, already has an FDA goal date set for the third quarter of 2026, with Takeda lined up to handle commercialization worldwide. That is a near-term catalyst most royalty purchases do not carry.
The broader portfolio backs up the confidence. Royalty Receipts grew 14% to $768 million in the second quarter of 2026, lifted by Tremfya, Voranigo, Imdelltra and Evrysdi, and the company raised its full-year 2026 guidance for Portfolio Receipts to a range of $3.4 billion to $3.5 billion, the second increase this year. Capital deployment has already topped $1 billion in 2026, including a July 2026 royalty purchase tied to AstraZeneca's cliramitug, pushing the development-stage pipeline to 19 potential therapies. Even after repaying a $380 million term loan in July 2026, Royalty Pharma still paid a quarterly dividend of $0.235 per share and bought back $45 million of stock in the second quarter alone.
Not every royalty ages well, and Royalty Pharma's own numbers show it. Promacta royalties fell 75% in the second quarter of 2026 to just $8 million as US generic competition took hold, and Imbruvica payments slipped 16% to $36 million, a reminder that patent cliffs eventually catch up to even the steadiest cash flows. That same risk sits underneath every new deal the company signs, including the one with Zealand.
The rusfertide agreement carries its own strings. Royalty Pharma's 1% royalty stops scaling once global sales pass $1.5 billion, at which point Zealand keeps a 0.25% cut and Royalty Pharma only 0.75%, so the largest commercial outcomes get split rather than fully captured. And rusfertide still has not cleared the FDA. The agency's goal date only falls in the third quarter of 2026, meaning the second $50 million payment is committed before regulators finish their review. Layer that onto a balance sheet carrying $9.2 billion in total debt principal against $812 million of cash as of June 30, 2026, and it becomes clear this is a company funding new bets with borrowed as w

Kate Beckinsale has compared navigating post-traumatic stress disorder (PTSD) to living in "hell".
Returning to Instagram on Wednesday, the Serendipity actress opened up about the mental health condition, which a person can experience after witnessing a terrifying or traumatic event.
"(There are men, women and children all around the world) who have seen such absolute horror or experienced such absolute horror that their nervous system is permanently altered as a result," she began. "A lot of those people become incredibly good at masking it, and it's sad because they become so good that they get no grace whatsoever. They get up, they go to work, they provide for their family."
Beckinsale did not specify whether she has been diagnosed with PTSD. However, she urged her 5.3 million followers to be considerate of those who may be dealing with trauma.
"Given the fact that it's invisible and you can't know, maybe err on being on the gentler side with people, being kinder with people," the 53-year-old mused. "It really is true that if you haven't walked a mile in someone's shoes - however fancy you feel the shoes are - you have absolutely no idea what they may be carrying or masking or dealing with day and night."
In addition, Beckinsale claimed that research into PTSD and the female brain has only "begun to be studied in the last six, seven years".

#beckinsale

Kate Beckinsale opened up about PTSD and how it can deeply affect daily life and relationships
She urged people to show kindness, emphasizing that struggles like PTSD are often invisible to others
Beckinsale reflected on grief from losing her mother, sharing how it has impacted her mental and physical health
Kate Beckinsale is getting candid about how difficult navigating post-traumatic stress disorder (PTSD) can be.
On Wednesday, Sept. 2, the actress, 53, shared a video discussing PTSD and how it isn't fully understood or studied, especially among women. The post came just after the 53-year-old shared a slew of Instagram Stories about her late mother, Judy Loe, and her struggles with grief.

#sept

Acclaimed ****** anese artist Yayoi Kusama has passed away aged 97.
The popular artist, who was known for her colorful art installations and surreal sculptures, died at a hospital in Tokyo on Aug. 14, the Yayoi Kusama Studio confirmed. "She continued to paint until her final days, never setting aside her brush, and continued exploration of forever love and eternal soul," a statement from the studio read. "She continued to paint until her final days, never setting aside her brush, and continued exploration of forever love and eternal soul."
Born in 1929, Kusama was a prolific artist known for her embrace of colorful motifs, vibrant polka dot designs, and abstract expressionism. Outside of sculptures and installations, she also painted, did performance art, wrote poetry, and had frequent involvement in the fashion industry. Her work has been exhibited all over the world, including at the Museum of Modern Art in New York, the Tate Modern in London, and the National Museum of Modern Art in Tokyo.
Throughout her career, she was open about her mental health struggles and revealed that she suffered from obsessive-compulsive disorder, hallucinations, and mania.
COMPLEX SHOP: Shop the brands you love, anytime and anywhere. Uncover what's next. Buy. Collect. Obsess.

#artist #love #tokyo

Will Forte may be best known for making audiences laugh, but his life away from the screen is filled with unexpected stories. Born Orville Willis Forte IV, he went by Billy as a child before eventually adopting Will, the name that would follow him into his entertainment career. Long before Hollywood, his energetic personality was already evident through impressions, elaborate pranks and a competitive streak.
Growing up in California, Forte balanced comedy with athletics. He participated in football and swimming during high school and was voted "Best Personality" by his graduating class. Those early years revealed many of the qualities that would later become **** ociated with his comedy: persistence, unpredictability and a willingness to fully commit to whatever caught his attention.
Forte has also spoken publicly about living with obsessive compulsive disorder and how it can affect his behavior. One recurring tendency involves feeling compelled to complete tasks once he has started them. Whether working through a puzzle or finishing an everyday chore, walking away before reaching the end can be difficult. That intense focus has occasionally produced some unusual results outside his professional life.
One particularly memorable example involved the classic arcade game Donkey Kong. While working on a movie in 2011, Forte became fascinated with the game between scenes and devoted considerable time to improving his score. His dedication eventually became serious enough that he reportedly reached 36th place in the game's competitive rankings at one point. For someone primarily known as an actor and comedian, becoming a highly ranked Donkey Kong player was an appropriately unexpected achievement.
His personal life entered a new chapter after he met businesswoman Olivia Modling at a party in 2018. Their relationship developed away from much of Hollywood's attention, and the couple married in 2021. They have since welcomed two daughters, adding family life to Forte's increasingly varied list of roles.

#forte

The FDA approved Pasatru, whose generic name is garetosmab, of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for adults with fibrodysplasia ossificans progressiva. FOP is an ultra-rare genetic disorder in which bone forms inside muscles, tendons, and ligaments, progressively restricting movement. In a 56-week Phase 3 trial involving 63 adults, the approved 3-milligram-per-kilogram dose reduced the number of new abnormal bone lesions by 94% compared with placebo. The decision completed an unusual clinical recovery. Regeneron paused an earlier study in 2020 after five patients died during its open-label portion, when all participants were receiving active treatment. The published ****** ysis later considered a relationship to treatment unlikely, although causality could not be ruled out. For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Pasatru is a regulatory and scientific victory whose earnings potential is constrained by an exceptionally small market.
The company's existing scale makes that limitation difficult to ignore. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) generated second-quarter revenue of $4.29 billion, up 17%, while company-defined non-GAAP diluted EPS reached $14.29. Global Dupixent sales, recorded by partner Sanofi, increased 38% to approximately $6 billion, and U.S. Eylea HD sales rose 52% to $596 million. Against those franchises, even a successful Pasatru launch would have limited influence on consolidated results.
The approval demonstrates that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) can recover a program after a major clinical setback. Following the 2020 dosing pause, the company worked with regulators to design a late-stage study that produced a statistically significant reduction in new bone lesions. Pasatru also validates research into Activin A, which activates the mutant ACVR1/ALK2 receptor and triggers abnormal bone formation in FOP.
That platform value may matter more than initial sales. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) plans to begin a pediatric trial later in 2026, which could eventually expand the eligible population. The regulatory recovery may also strengthen confidence in the company's ability to advance other rare-disease programs from internally discovered biology.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is entering an exceptionally small pharmaceutical market. Published prevalence estimates generally range from approximately one case per one million to one per two million people. Only approximately 800 to 900 known or confirmed cases have been identified globally, although additional patients may remain undiagnosed. Pasatru is currently approved only for adults, further narrowing its immediate market.

#regeneron #pasatru #adults #market

Celtic and Rangers have both been ordered to play their next home Scottish Cup matches behind closed doors after last season's quarter-final was marred by fan disorder.
Both clubs will also have to pay £100,000 to the team they are drawn against in that fixture.
The two clubs could also face a second home match without fans if there is a further incident of either side's supporters engaging in "unacceptable conduct" in a Scottish Cup fixture.
Celtic progressed to last season's semi-finals by beating Rangers on penalties at Ibrox, after which fans of both teams spilled on to the pitch.
The sanctions are likely to come into force when both sides enter this season's Scottish Cup in January.

#scottish

Rangers have confirmed they will provide Celtic with 300 tickets for the League Cup quarter-final at Ibrox on 13 September.
The most recent meeting of the sides at Ibrox came in the Scottish Cup on 8 March and was marred by fan disorder. Earlier on Friday, the Scottish FA announced both clubs would have to play their next home Scottish Cup games behind closed doors.
About 8,000 Celtic supporters had attended the 8 March match while recent league encounters of the Glasgow clubs had away support in the low thousands.
And Rangers said: "Since the clubs last considered away allocations, the Blackbourne Report has been published and our sanction issued.
"Together with the events of 8 March and our ******* sment of the current risk, these developments have informed our planning for this fixture [on 13 September]. Matchday safety remains our top priority.

#scottish #clubs #september

Pharmaceutical giant Johnson & Johnson (NYSE:JNJ) is one of Jim Cramer's favorite stocks in the sector. Over the course of this year, the CNBC TV host has praised the firm on multiple occasions. Among the reasons that he has been optimistic about Johnson & Johnson (NYSE:JNJ) include the firm's cancer drug portfolio and its Triple A balance sheet. For instance, in his July 6th appearance on Mad Money, Cramer remarked that "P&Gs and the J&Js in your portfolio allow you to safely own the techs." With tech stocks struggling recent due to concerns about the data center buildout, it was unsurprising that Johnson & Johnson (NYSE:JNJ) popped up on his radar once again on August 24th:
"I've been using that one stock JNJ to be able to [example] becuase it has a better balance sheet at this point than the US government, it doesn't need money, it's got very good science. It's not hostage to the government right now. It's got more new drugs than any of the, 18 new compounds, could be a billion dollars. And I come back and say, all right, well that's the treasury, plus the upside."
Johnson & Johnson (NYSE:JNJ)'s shares are up by more than 50% over the past year. Cramer's optimism about the firm covers several, but not all, aspects of the debate surrounding the firm. While Johnson & Johnson (NYSE:JNJ) has raised its full-year revenue guidance to a midpoint of $101 billion, removed headwinds related to its longstanding talcum powder lawsuits and posted strong growth with its Darzalex and Tremfya drugs for myeloma and psoriasis, concerns about its MedTech growth, flat profits growth and a 55.7% sales hit to its immune system disorders drug Stelara continue to raise the potential for headwinds.
For instance, Johnson & Johnson (NYSE:JNJ)'s MedTech business grew by a mere 3.6% in the second quarter as it was impacted by a slowdown in sales of heart-recovery devices following a study in the United Kingdom. Additionally, for a firm that's struggling on the net income growth front, $5.5 billion in talc powder settlements will continue to be a headwind to the cash flow. Johnson & Johnson (NYSE:JNJ) is due to pay $3 billion out of the $5.5 billion in 2027. Yet, at the same time, the diversified business nature means that some segments are growing. One example is the Innovative Medicine Business, which grew by 6.8% to $16.4 billion revenue, due to Darzalex and Tremfya.
Looking at hedge fund sentiment, while 113 out of the 1,022 funds part of Insider Monkey's Q1 database had held a stake in Johnson & Johnson (NYSE:JNJ), the figure jumped to 117 out of 1,006 funds in Q2. Among the notable additions was Polar Capital's $199 million stake, while Fisher ****** et Management ****** ped its stake by 44% to $3.3 billion. On the valuation front, Johnson & Johnson (NYSE:JNJ) trades at a forward P/E ratio of 23.4,2 which is lower than MRK's 56.82 and higher than AbbVie's 18.83. Shares short as a percentage of float are negligible at roughly 1%.

#billion #tremfya

The fallout from owner Jed York's arrest continues to hang over the San Francisco 49ers, but NBC Sports Bay Area's Matt Maiocco doesn't believe it will cost the York family the franchise.
York was charged with two misdemeanors — disorderly conduct and possession of criminal tools — after responding to an undercover ad on what was described as a known prostitution website. He received a two-day jail sentence and a $1,150 fine. NFL commissioner Roger Goodell confirmed at the league's preseason owners' meeting that the incident is being reviewed under the personal conduct policy. York did not attend the meeting, a decision that wasn't surprising given how recent the arrest was.
Speaking on KNBR, Maiocco addressed the inevitable speculation about a forced sale directly, pointing to how deliberately the York family structured its ownership just two years ago.
"I can't see that. Jed bought equity from his mom in order to become the principal owner. Yes, the 49ers raised a lot of money by selling off around 9.7% of the organization, but when they transferred ownership officially over to Jed as the principal owner, the idea was this was a move made to ensure that it remained in the family," Maiocco said. "I would imagine the long-term plan is for Jed to hand it over to one of his sons or keep it in the family. I don't think this [arrest] will impact that. I think that there will be some discipline by commissioner Roger Goodell. I think it can happen sooner rather than later because the legal process has run its course. I would expect a fine and even a suspension, where he has to stay away from the team for a certain amount of time."
York became the 49ers' principal owner in March 2024, purchasing additional equity from his family specifically to formalize what had effectively been his role since taking over as CEO in 2010. At the time, York did frame the move as a long-term succession plan, saying it was "reflective of how we've operated" and intended to keep the team "in our family for generations to come." His mother, Denise DeBartolo York, and father, Dr. John York, remained co-chairs.

#think #Roger #goodell

An incident during which England bowler Brydon Carse was handcuffed outside a nightclub is being investigated by Derbyshire Police, who say they are looking into allegations of **** ault.
Images circulating on social media on Sunday showed Carse in handcuffs and surrounded by police officers while the pace bowler was on a night out in Derby on Saturday.
The 31-year-old was briefly arrested on suspicion of being drunk and disorderly.
The England and Wales Cricket Board (ECB) said the incident would be investigated by the Cricket Regulator and, as a result, Carse was removed from the England squad for the second Test against Pakistan.
On Monday, Derbyshire Police said a man had been briefly detained outside Molly Malone's bar, before being released.

#derbyshire #Cricket